Presentation of 1-year IVAN and 2-year CATT study results

April 18th, 2012
Rockville, Md.: ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

These two multicenter randomized clinical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Eye Institute, respectively, evaluate the relative efficacy and safety of Lucentis and Avastin in the management of neovascular age-related macular degeneration (AMD).

The presentation will also live-streamed at http://prolibraries.com/arvo/registration/event. While annual meeting registration is required for the session in Fort Lauderdale, the online is event is free.

The 2012 ARVO Annual Meeting, Translational Research: Seeing the Possibilities, takes place May 6 – 10 in Fort Lauderdale, Fla. Registration information can be found at www.arvo.org/am.

Provided by Association for Research in Vision and Ophthalmology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Solar Impulse 2 pilot becomes aviation legend

At 62 years of age, Swiss Solar Impulse 2 pilot Andre Borschberg has made aviation history with a record breaking solo flight across the Pacific that he has called "an interior journey".

Mexico City proposes regulations for Uber

Mexico City is proposing regulations that would allow Uber and other smartphone-based ride-sharing apps to operate, while requiring drivers and cars to be registered, the city's Office of Legal and Legislative Studies said ...

Researchers discover new mechanism of DNA repair

The DNA molecule is chemically unstable giving rise to DNA lesions of different nature. That is why DNA damage detection, signaling and repair, collectively known as the DNA damage response, are needed.